Geschäftskunden Kundenprogramme
Vor Ort
Merkzettel Warenkorb
  • Produktbild: Thrombolytic Therapy in Acute Ischemic Stroke II
  • Produktbild: Thrombolytic Therapy in Acute Ischemic Stroke II

Thrombolytic Therapy in Acute Ischemic Stroke II

Fr. 137.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

03.06.1993

Herausgeber

Gregory J. DelZoppo + weitere

Verlag

Springer Berlin

Seitenzahl

334

Maße (L/B/H)

23.5/15.5/2 cm

Gewicht

534 g

Sprache

Englisch

ISBN

978-3-540-56442-3

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

03.06.1993

Herausgeber

Verlag

Springer Berlin

Seitenzahl

334

Maße (L/B/H)

23.5/15.5/2 cm

Gewicht

534 g

Sprache

Englisch

ISBN

978-3-540-56442-3

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Thrombolytic Therapy in Acute Ischemic Stroke II
  • Produktbild: Thrombolytic Therapy in Acute Ischemic Stroke II
  • Background to Thrombolytic Therapy in Acute Ischemic Stroke.- Therapy for Acute Ischemic Stroke: Clinical Needs and Statistical Burdens.- Clinical Outcome of Acute Ischemic Stroke: Prospective Angiographic Studies.- The Ischemic Penumbra: Usefulness of PET.- Thrombolytic Agents: Lessons for Their Use in Acute Stroke from Myocardial Infarction Experience.- Pathogenesis of Secondary Brain Hemorrhage After Ischemia: Lessons from Animal Models … and a few from man, too!.- Clinical Trials of Fibrinolytic Agents in Carotid Territory Cerebral Ischemia.- Symptom-Based Trials of Intravenous rt-PA in Acute Stroke.- A Safety and Efficacy Study of Intravenous rt-PA in Patients with Acute Stroke.- Recanalization, Infarct Volume, Cerebral Hemorrhage, and Clinical Outcome After Intravenous Recombinant Tissue Plasminogen Activator and Heparin in Acute Carotid Territory Stroke.- Intravenous Tissue Plasminogen Activator in Acute Thromboembolic Stroke: A Placebo-Controlled, Double-Blind Trial.- The European Cooperative Acute Stroke Study (ECASS).- On the Estimation of the Sample Size for the ECASS Study.- Australian Streptokinase Trial (ASK).- Thrombolytic and Antithrombotic Therapy in Acute Ischemic Stroke. Multicenter Acute Stroke Trial — Italy (MAST-I).- Discussion Summary: Clinical Trials in Progress.- Other Applications of Fibrinolytic Agents in the Central Nervous System.- Acute Central Retinal Artery Occlusion and the Role of Thrombolysis.- Current Status of Fibrinolysis for the Rapid Dissolution of Subarachnoid and Intraventricular Clot.- Discussion Summary: Other Applications of Fibrinolytic Agents in the Central Nervous System.- Insights into the Pathogenesis of Cerebral Ischemia Relevant to Fibrinolysis.- Deterioration of Acute Stroke.- Early Spontaneous Recanalization of Thromboembolic Stroke.- Spectacular Shrinking Deficits in Acute Ischemic Stroke.- The Significance of Various Factors Associated with Hemorrhagic Transformation in Patients Treated with Recombinant Tissue Plasminogen Activator for Acute Stroke.- Thrombolysis: Stroke Subtype and Embolus Type.- The Prognostic Value of Collateral Blood Flow in Acute Middle Cerebral Artery Occlusion.- Morphological Evidence of Progressive Microvascular Impairment in Middle Cerebral Artery Occlusion-Reperfusion.- Discussion Summary: Insights into the Pathogenesis of Cerebral Ischemia Relevant to Fibrinolysis.- Diagnosis and Assessment of Outcomes in Acute Cerebral Ischemia.- The Relevance of CT Scanning and Angiography for Patients with Acute Stroke Treated with Recombinant Tissue Plasminogen Activator.- Recanalization of the Embolically Occluded Middle Cerebral Artery in Acute Stroke Patients: Noninvasive Assessment and Outcome.- Potential Role of Magnetic Resonance Imaging in Selecting Patients for Thrombolytic Therapy.- The Role of SPECT in Acute Stroke Thrombolysis.- Clinical and Brain Hemodynamic Evaluations of Thrombolytic Therapy in Acute Ischemic Stroke: SPECT Study.- The Relevance of Neurological and Functional Outcome Scales for Acute Stroke Trials.- Discussion Summary: Diagnosis and Assessment of Outcomes in Acute Cerebral Ischemia.- Ancillary Therapy for Cerebrovascular Reperfusion.- Neuronal Protection and Recanalization Strategies: Is More Better?.- Strategies Which Decrease Post-Reperfusion Lipid Peroxidation.- Anti-PMN Leukocyte Strategies and Their Application to Focal Cerebral Ischemia.- Von Willebrand Factor as a Target for Antithrombotic Intervention.- Neuronal Protection: Is There a Role for Gangliosides or Ca2+-Channel Blockers?.- Discussion Summary: Ancillary Therapy for Cerebrovascular Reperfusion.- Open Communications.- A Meta-Analysis of All Published Data on the Use of Thrombolytic Therapy to Treat Acute Ischemic Stroke.- Causes of Delayed Treatment of Stroke Patients Enrolled in t-PA Protocols.- A Demming Approach to Recruiting: The National Institute of Neurological Disease and Stroke (NINDS) t-PA Stroke Trial Experience.- Local Intra-arterial Fibrinolytic Therapy Within the Cerebral Arteries: Effectiveness of rt-PA Concerning Recanalization Rate and Time.- Relation of Thrombolytic Reperfusion and of Collateral Circulation to Outcome in Patients Suffering Cerebral Main Artery Occlusion.- Factors Related to Intracranial Hematoma Formation in Patients Receiving t-PA for Acute Ischemic Stroke.- Transcranial Doppler Sonographic (TCD) Monitoring of Basilar Artery Thrombolysis.- HMPAO SPECT Measures Reperfusion After Thrombolytic Therapy in Acute Stroke.- A Cell Culture Model of Reperfusion Injury: Neutrophil-Mediated Brain Endothelial Cytotoxicity.- Modification of Brain Ischemia Due to Embolic Stroke by Tissue-Type Plasminogen Activator With and Without Heparin in a Rabbit Model.- Reduction of Infarct Volume and Mortality by Thrombolysis with rt-PA in an Embolic Stroke Model.- Discussion Summary: Open Communications.- Clinical Trial Development.- Clinical Trials Sponsored by Companies Versus the NIH.- Blindness and Thrombolysis.